missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Human Polypeptide GalNAc Transferase 3/GALNT3 Antibody, R&D Systems™

Sheep Polyclonal Antibody
Brand: R&D Systems AF7174
This item is not returnable.
View return policy
Description
Polypeptide GalNac Transferase 3/GALNT3 Polyclonal specifically detects Polypeptide GalNac Transferase 3/GALNT3 in Human samples. It is validated for Western Blot, Immunocytochemistry.
Specifications
| Polypeptide GalNac Transferase 3/GALNT3 | |
| Polyclonal | |
| Unconjugated | |
| Q14435 | |
| GALNT3 | |
| Mouse myeloma cell line NS0-derived recombinant human Polypeptide GalNac Transferase 3/GALNT3 Gln38-Asp633 Accession # Q14435 | |
| 100 μg | |
| Primary | |
| Detects human Polypeptide GalNac Transferase 3/GALNT3 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) GALNT1 and rhGALNT4 is observed. | |
| Human | |
| IgG |
| Western Blot, Immunocytochemistry | |
| LYOPH | |
| Western Blot 0.5 ug/mL, Immunocytochemistry 5-15 ug/mL | |
| EC 2.4.1.41, GalNAc transferase 3, GalNAc-T3, GalNAc-T3DKFZp686C10199, HFTC, HFTCMGC61909, HHS, HHSPolypeptide GalNAc transferase 3, polypeptide GalNAc-transferase T3, polypeptide N-acetylgalactosaminyltransferase 3, pp-GaNTase 3, Protein-UDP acetylgalactosaminyltransferase 3, UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3, UDP-N-acetyl-alpha-D-galactosamine:polypeptideN-acetylgalactosaminyltransferase 3 (GalNAc-T3) | |
| Sheep | |
| Affinity Purified | |
| RUO | |
| 2591 | |
| Sterile PBS to a final concentration of 0.2 mg/mL. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction